NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05252390
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
About the Study
NOTE: This study is no longer recruiting patients.
This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a in people with advanced . The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or cancers only.
NOTE: This study is no longer recruiting patients.
NOTE: This study is no longer recruiting patients.